P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1D
12. okt., 09:49:20 GMT +8 · SGD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za P8A …
Tržna kapitalizacija
32,37 mio.
Povprečni promet
1,32 tis.
Promet
0,00
52-tedenski najvišji tečaj
0,26 SGD
52-tedenski najnižji tečaj
0,10 SGD
Čisti dobiček na delnico
−0,04 SGD
Št. izdanih delnic
267,53 mio.
Št. zaposlenih
111
Tržna kapitalizacija
32,37 mio.
Povprečni promet
1,32 tis.
Promet
0,00
52-tedenski najvišji tečaj
0,26 SGD
52-tedenski najnižji tečaj
0,10 SGD
Čisti dobiček na delnico
−0,04 SGD
Št. izdanih delnic
267,53 mio.
Št. zaposlenih
111
Novice
Iz spletnih virov in novičarskih partnerjev
Yahoo Finance
·
pred 46 minutami
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
Simply Wall Street
·
pred 56 minutami
Did Genetic Response Data Just Shift Madrigal Pharmaceuticals (MDGL) Investment Narrative?
MarketWatch
·
pred 1 uro
It was another great week for the average stock as market leadership shifts away from tech
CNN
·
pred 17 urami
Nasdaq sinks more than 2% as investors raise questions about AI debt
Profil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Vizitka: Cordlife Group Ltd
Generalni direktorYiu Pang Fai
Št. zaposlenih111
Ustanovljeno2. maj 2001
Sedež-
Sektor-
Spletno mestocordlife.com